FDA Approves Blenrep: GSK Blood Cancer Drug with Unique History
- The food and Drug Management (FDA) issued a partial approval of GSK's Blenrep (belantamab mafodotin-blmf) on December 14, 2023, for the treatment of patients with relapsed or refractory...
- Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell.
- Blenrep is a B-cell maturation antigen (BCMA)-directed antibody and alkylating agent.
“`html
FDA Approves Blenrep for Multiple Myeloma in limited Combination, Rejects Another
The food and Drug Management (FDA) issued a partial approval of GSK’s Blenrep (belantamab mafodotin-blmf) on December 14, 2023, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The agency approved Blenrep in combination with bortezomib and dexamethasone, but concurrently rejected its use in combination with pomalidomide and dexamethasone, citing a lack of evidence supporting its benefit in that regimen. this decision marks a critically importent, though complex, development in the treatment landscape for this aggressive blood cancer.
Background on Blenrep and Multiple Myeloma
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell. According to the American Cancer Society, approximately 35,730 adults will be diagnosed with multiple myeloma in the United States in 2023, and an estimated 12,540 will die from the disease (American Cancer Society, 2023). Treatment options have expanded in recent years, but relapse remains a significant challenge for many patients.
Blenrep is a B-cell maturation antigen (BCMA)-directed antibody and alkylating agent. It works by targeting BCMA, a protein found on the surface of myeloma cells, and delivering a toxic payload to kill them.The drug initially received accelerated approval in 2020, but faced setbacks due to safety concerns and subsequent clinical trial results.
The DREAMM Trials: A Closer Look
GSK submitted data from two key clinical trials to the FDA: DREAMM-7 and DREAMM-8. Both trials evaluated Blenrep in combination with other standard-of-care treatments for patients with relapsed or refractory multiple myeloma.
| Trial | Combination | Key Findings |
|---|---|---|
| DREAMM-7 | Blenrep + Bortezomib + Dexamethasone | Demonstrated a statistically significant enhancement in progression-free survival and overall survival. (stat News, 2024) |
| DREAMM-8 | Blenrep + Pomalidomide + Dexamethasone | Showed a reduction in the risk of disease progression or death, but the FDA determined the benefit did not outweigh the risks. (stat News, 2024) |
The positive results from DREAMM-7, especially the demonstrated overall survival benefit, were crucial in securing the approval for the Blenrep, bortezomib, and dexamethasone combination. The FDA’s rejection of the Blenrep, pomalidomide, and dexamethasone combination suggests concerns about the risk-benefit profile of that specific regimen.
FDA’s reasoning and Future Implications
The FDA’s decision highlights the agency’s rigorous evaluation process and its commitment to ensuring that new treatments offer a meaningful benefit to patients. While the DREAMM-8 trial showed some efficacy, the FDA apparently determined that the observed benefits were not ample enough to justify the risks associated with the combination